MedTrace Logo

Double-Blind, Placebo-Controlled Trial of Eefooton in Patients With Chronic Kidney Disease

NCT05227313 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2022-03-02

No results posted yet for this study

Summary

This phase II study, 24-week, double-blind, study evaluated Eefooton's safety and efficacy for patients with CKD stage 3 to 4 Not on dialysis.

Conditions

  • Chronic Kidney Diseases
  • Renal Insufficiency, Chronic
  • Urologic Diseases

Interventions

DIETARY_SUPPLEMENT

Eefooton oral solution

Eefooton is extracted from Rhodiola, Huang Qi, American Ginseng, Dang Ginseng, and Ligustrum lucidum by biotechnology. It has immunomodulatory effects, anti-oxidation and anti-inflammatory effects, and regulates calcium metabolism.

DIETARY_SUPPLEMENT

Placebo oral solution

oral solution matched placebo

Sponsors & Collaborators

  • Morris Enterprise Co.,Ltd.

    collaborator UNKNOWN

  • Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation

    lead OTHER

Principal Investigators

  • Kuo-Cheng Lu, Ph.D · Taichung Tzu Chi Hospital

  • Chen-Shiung Wu, Ph.D · Taichung Tzu Chi Hospital

  • Ching-Hsiu Peng, MD · Taichung Tzu Chi Hospital

  • Ko-Lin Kuo, MD · Taichung Tzu Chi Hospital

  • Yi-Chun Wang, MD · Taichung Tzu Chi Hospital

  • Ding-Jun Lin Lin, MD · Taichung Tzu Chi Hospital

  • Szu-Chun Hung, MD · Taichung Tzu Chi Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Taiwan

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05227313 on ClinicalTrials.gov